Research Suggests Powerful Cancer Prevention Combo: GLP-1RAs and Progestins for Women at Risk
New Hope for Women Facing Endometrial Cancer Risks
Endometrial cancer is now the most common gynecologic cancer in developed countries, with cases on the rise—especially among women with obesity and metabolic disorders. Traditional prevention and management rely on progestin therapy, but with the obesity epidemic, more effective strategies are urgently needed. Could medications originally designed for diabetes and weight loss hold the answer?
Study Design: Comparing Therapies in a Massive Cohort
Researchers analyzed real-world health data from over 444,000 women with noncancerous uterine conditions or endometrial hyperplasia (a cancer precursor). Participants received either progestins alone or in combination with other drugs, such as GLP-1 receptor agonists (GLP-1RAs, medications often prescribed for diabetes and weight management) and/or metformin.
The aim: To see if adding GLP-1RAs to progestin therapy would lower the risk of developing endometrial cancer compared to progestin alone or with other metabolic drugs.
Key Findings: A Game-Changer for Prevention
Dramatic Risk Reduction: Women who used both GLP-1RAs and progestins had a 66% lower risk of developing endometrial cancer than those using progestins alone (HR 0.34).
Consistent Benefits: This risk reduction held true across all subgroups—regardless of age, body mass index (BMI), menopause status, or progestin type (oral or intrauterine).
Better Than Metformin: GLP-1RA plus progestin therapy was even more effective than metformin plus progestin.
Triple Therapy Triumphs: Adding both GLP-1RA and metformin to progestin gave the greatest cancer protection.
Fewer Hysterectomies: Women on the GLP-1RA plus progestin combo were also less likely to need a hysterectomy at two and five years.
How Does It Work?
GLP-1 receptor agonists, widely used for diabetes and weight loss, may also help the uterus respond better to progestins, breaking through resistance and directly reducing cancer risk—even in high-risk women with obesity or diabetes.
Why This Matters
This research opens new doors for women at risk of endometrial cancer, especially those with metabolic issues. By safely combining existing medications, doctors may be able to offer better protection without resorting to surgery.
Key Takeaways
Combining GLP-1 receptor agonists with progestins could significantly lower endometrial cancer risk.
The benefit is robust, regardless of weight, age, or menopause status.
Triple therapy (GLP-1RA + metformin + progestin) shows the strongest protection.
The approach may also reduce the need for hysterectomy.
Results suggest a promising new strategy for cancer prevention in women with benign uterine disease or hyperplasia.
Citation:
Yen TT, Hsieh TYJ, Lee GY, Toy EP, Wei JC-C, Tanner EJ. GLP-1 Receptor Agonists Plus Progestins and Endometrial Cancer Risk in Nonmalignant Uterine Diseases. JAMA Network Open. 2026;9(2):e2558205. doi:10.1001/jamanetworkopen.2025.58205.
